Job offersmore »
- Department Chair and Professor of Human Ecology - Davis (CA) USA
- Factory Manager Assistant - Huizhou, China
- Internal Salesperson - Netherlands
- Crop Manager - Northern France
- Farm General Manager - Egypt
- Grower (cucumbers) - Australia
- Projectleider Export - Maasdijk, Nederland
- Sales representative - Eastern PA, DE, MD, VA & WV, USA
- Sales representative - Michigan, USA
- Assistant Grower - Delta (BC), Canada
Top 5 - yesterday
Top 5 - last week
Top 5 - last month
- Klasmann-Deilmann takes over international distribution of Growcoon
- US: Patent for cooling method of electrical components in a geothermal well
- Netherlands: First well of geothermal doublet for ECW Andijk
- Soil to hydroponics: 50%-100%+ increase in tomato and pepper production
- Pythium root rot on hydroponically grown basil and spinach
Exchange ratesmore »
Inocucor accelerates commercialization with $9.5 million investmentInocucor uses a patented fermentation process to combine multi-strains of bacteria, yeasts and fungi into powerful biostimulants that naturally improve crop yields, shorten growing periods and create healthier, more resilient soils for farmers and greenhouse growers. A suite of microbial biocontrol products that target devastating diseases in potatoes, tomatoes and strawberries is also under development.
“We’ve come a long way in a few short years, with two products in use in the field, a signature line of biocontrol products under development and hundreds of field trials underway throughout the Americas,” said Inocucor’s President and CEO Donald R. Marvin. “Our business strategy and plan are guided by our vision for a Second Green Revolution for agriculture, one that uses earth-friendly farming products to improve crop yields, revitalize soils and improve water quality.”
Early next spring, Inocucor will occupy its new 30,000-square-foot U.S. headquarters and commercialization office currently under construction in Centennial, Colo. Its Montreal-based, R&D-focused Technical Center of Excellence is currently being enlarged from 10,000 to 20,000 square feet to house expanded product development and manufacturing operations. The company employs about 40 people in Montreal and the U.S., and anticipates adding another 25 to 30 high-level scientific and managerial professionals over the next year.
$9.5 million funding
Inocucor Corporation announced the $9.5 million USD ($12.1M CAD) second close of its Series B financing round. Funds raised to date in its Series B round now total $38.5 million USD ($50.9 million CAD).
The round was led by Pontifax AgTech, a growth capital investor in the global food and agriculture sector.
Other participants in the second Series B round include existing investors Cycle Capital Management (Montreal), Desjardins Innovatech (Montreal) and Cairn Investments (Denver). Inocucor’s first Series B equity financing of $29 million USD ($38.8 million CAD) in March 2017 was led by TPG ART with participation from existing investors.
Funds will enable Inocucor to accelerate its commercialization activities, through the increased production and marketing of its first- and second-generation biostimulant products, Synergro and Synergro Free. They will also advance development of a new suite of biocontrol products that combat economically devastating diseases in high-value crops such as strawberries, tomatoes and potatoes.
For more information
Publication date: 1/9/2018
Other news in this sector: